Nurix Therapeutics, Inc.
NRIX
$15.60
-$0.13-0.83%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 83.98M | 83.69M | 88.38M | 56.42M | 54.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.98M | 83.69M | 88.38M | 56.42M | 54.55M |
| Cost of Revenue | 316.90M | 301.10M | 270.46M | 241.29M | 221.63M |
| Gross Profit | -232.92M | -217.42M | -182.08M | -184.87M | -167.08M |
| SG&A Expenses | 52.74M | 49.81M | 48.37M | 45.80M | 45.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 369.65M | 350.92M | 318.84M | 287.09M | 267.58M |
| Operating Income | -285.67M | -267.23M | -230.45M | -230.67M | -213.03M |
| Income Before Tax | -263.70M | -244.02M | -206.47M | -208.22M | -193.30M |
| Income Tax Expenses | 760.00K | 768.00K | 850.00K | 180.00K | 270.00K |
| Earnings from Continuing Operations | -264.46 | -244.79 | -207.32 | -208.40 | -193.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -264.46M | -244.79M | -207.32M | -208.40M | -193.57M |
| EBIT | -285.67M | -267.23M | -230.45M | -230.67M | -213.03M |
| EBITDA | -277.53M | -259.36M | -222.22M | -222.35M | -205.01M |
| EPS Basic | -3.04 | -2.97 | -2.61 | -2.81 | -2.89 |
| Normalized Basic EPS | -1.90 | -1.85 | -1.63 | -1.75 | -1.80 |
| EPS Diluted | -3.04 | -2.97 | -2.61 | -2.81 | -2.89 |
| Normalized Diluted EPS | -1.90 | -1.85 | -1.63 | -1.75 | -1.80 |
| Average Basic Shares Outstanding | 346.69M | 330.01M | 318.63M | 297.13M | 268.47M |
| Average Diluted Shares Outstanding | 346.69M | 330.01M | 318.63M | 297.13M | 268.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |